



**Ziad S. Ojakli**  
Group Vice President  
Government & Community Relations

1350 I Street NW  
Washington, DC 20005 USA

February 28, 2007

The Honorable Henry Waxman  
United States House of Representatives  
Washington, DC 20515

Dear Mr. Waxman:

Thank you for sponsoring the "Access to Life Saving Medicine Act of 2007." We are pleased to offer our strong support for this important legislation. As you know, this bill represents a significant first step towards making safe, effective, and affordable biogenerics available to Americans by defining a clear legal course for the Food and Drug Administration (FDA) to establish an approval criteria and process.

In 2006, Ford Motor Company spent \$3.1 billion on health care in the United States alone. In other words- \$1,200 for every American-made Ford vehicle. Biologic costs accounted for tens of millions of this overall amount and their costs are increasing rapidly – faster than the rapid rise of overall health care costs. While this steep increase reflects recent medical technology advances, it is largely attributed to current practices that allow biologic manufacturers to enjoy monopoly pricing through market exclusivity.

Granting the FDA expanded approval authority will lead to a competitive marketplace for biologics. After the original manufacturer has enjoyed a reasonable period of market exclusivity, the FDA will help ensure that generic biologics are safe and effective before they reach the consumer. This critical advancement will help Ford Motor Company and other American manufacturers maintain cost-effective health care coverage for our employees and retirees.

Ford Motor Company applauds your leadership in introducing this important bipartisan legislation. We look forward to working with you to advocate for its timely passage.

Sincerely,

